Planta Medica International Open 2017; 4(S 01): S1-S202
DOI: 10.1055/s-0037-1608173
Poster Session
Georg Thieme Verlag KG Stuttgart · New York

Antipsoriatic potential of Pereskia aculeata Miller leaves

N Pinto
1   Laboratory of Bioactive Natural Products, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil
,
R Mendes
1   Laboratory of Bioactive Natural Products, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil
,
J Silva
1   Laboratory of Bioactive Natural Products, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil
,
P Duque Ana
1   Laboratory of Bioactive Natural Products, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil
,
C Castañon Maria
2   Department of Morphology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil
,
E Scio
1   Laboratory of Bioactive Natural Products, Department of Biochemistry, Federal University of Juiz de Fora, Juiz de Fora, Brazil
› Author Affiliations
Further Information

Publication History

Publication Date:
24 October 2017 (online)

 
 

    Preliminary studies had shown the marked anti-inflammatory potential of Pereskia aculeata leaves [1]. Psoriasis is a chronic inflammatory disease which affects 1 – 3% of the world Caucasian population [2], which encouraged the investigation of P. aculeata antipsoriatic potential by the mouse tail test [3]. Topical pharmaceutical formulations (20 mg) containing 6% or 12% of hexane fraction from P. aculeata leaves (HF), vehicle or PsorexTM were topically applied on the tail of Swiss mice (n = 5) and histometric analysis were performed as follows: (1) the total length of the scale region; (2) the length of the granular layer of the scale region; (3) the orthokeratosis degree, which was calculated by the ratio of (2)/(1). ANOVA followed by the Newman-Keuls test was used for statistical analysis (COBEA – Protocol n° 028/2014). The orthokeratosis degree presents high correlation with the antipsoriatic activity on human skin. The naive group and the topical pharmaceutical formulations containing vehicle, HF 6%, HF 12% or PsorexTM showed, respectively, 49.62 ± 3.1, 52.25 ± 4.5, 72.16 ± 3,3***, 78.14 ± 3.1***, and 86.83 ± 2.5*** of orthokeratosis degree (***p < 0.001 vs naive). Photomicrographs of the naïve and treated tissues are shown in Figure 1. Our findings strongly suggested that P. aculeata is endowed with antipsoriatic potential.

    Zoom Image
    Fig. 1: (A) naive, (B) Vehicle, (C) Psorex™, (D) HF 6%, (E) HF 12%. The arrows indicate the granular layer induced by sample application. The double arrows evidenced the epidermal thickness. In most cases, the increase of the epidermal thickness is correlated to the antipsoriatic potential of a tested drug.

    This work was supported by the grants from FAPEMIG, CAPES and CNPq.

    [1] Pinto NCC, Machado DC, Da Silva JM, Conegundes JL, Gualberto AC, Gameiro J, Chedier LM, Castañon MC, Scio E. J Ethnopharmacol 2015; 173: 330 – 337

    [2] Uva L, Miguel D, Pinheiro A, Antunes J, Cruz D, Ferreira J, Filipe P. Int J Endrocrinol 2012; 2012: 1 – 16.

    [3] Bosman B, Matthiesen T, Hess V, Friderichs E. Skin Pharmacol 1992; 5: 41 – 48.


    #
     
    Zoom Image
    Fig. 1: (A) naive, (B) Vehicle, (C) Psorex™, (D) HF 6%, (E) HF 12%. The arrows indicate the granular layer induced by sample application. The double arrows evidenced the epidermal thickness. In most cases, the increase of the epidermal thickness is correlated to the antipsoriatic potential of a tested drug.